These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 39042829)
21. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration. Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830 [TBL] [Abstract][Full Text] [Related]
22. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Jensen SA; Day ES; Ko CH; Hurley LA; Luciano JP; Kouri FM; Merkel TJ; Luthi AJ; Patel PC; Cutler JI; Daniel WL; Scott AW; Rotz MW; Meade TJ; Giljohann DA; Mirkin CA; Stegh AH Sci Transl Med; 2013 Oct; 5(209):209ra152. PubMed ID: 24174328 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Kim M; Ma DJ; Calligaris D; Zhang S; Feathers RW; Vaubel RA; Meaux I; Mladek AC; Parrish KE; Jin F; Barriere C; Debussche L; Watters J; Tian S; Decker PA; Eckel-Passow JE; Kitange GJ; Johnson AJ; Parney IF; Anastasiadis PZ; Agar NYR; Elmquist WF; Sarkaria JN Mol Cancer Ther; 2018 Sep; 17(9):1893-1901. PubMed ID: 29970480 [TBL] [Abstract][Full Text] [Related]
24. MSI1 associates glioblastoma radioresistance via homologous recombination repair, tumor invasion and cancer stem-like cell properties. Lin JC; Tsai JT; Chao TY; Ma HI; Chien CS; Liu WH Radiother Oncol; 2018 Nov; 129(2):352-363. PubMed ID: 30322656 [TBL] [Abstract][Full Text] [Related]
25. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer. Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417 [TBL] [Abstract][Full Text] [Related]
26. Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model. Andreou T; Williams J; Brownlie RJ; Salmond RJ; Watson E; Shaw G; Melcher A; Wurdak H; Short SC; Lorger M J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33707311 [TBL] [Abstract][Full Text] [Related]
27. Stimuli-Responsive Multifunctional Nanomedicine for Enhanced Glioblastoma Chemotherapy Augments Multistage Blood-to-Brain Trafficking and Tumor Targeting. Martins C; Araújo M; Malfanti A; Pacheco C; Smith SJ; Ucakar B; Rahman R; Aylott JW; Préat V; Sarmento B Small; 2023 Jun; 19(22):e2300029. PubMed ID: 36852650 [TBL] [Abstract][Full Text] [Related]
28. Targeted Brain Tumor Radiotherapy Using an Auger Emitter. Pirovano G; Jannetti SA; Carter LM; Sadique A; Kossatz S; Guru N; Demétrio De Souza França P; Maeda M; Zeglis BM; Lewis JS; Humm JL; Reiner T Clin Cancer Res; 2020 Jun; 26(12):2871-2881. PubMed ID: 32066626 [TBL] [Abstract][Full Text] [Related]
29. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797 [TBL] [Abstract][Full Text] [Related]
30. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival. Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730 [TBL] [Abstract][Full Text] [Related]
31. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment. Wang D; Wang C; Wang L; Chen Y Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355 [TBL] [Abstract][Full Text] [Related]
36. Gallego L; Ceña V Expert Opin Drug Deliv; 2020 Nov; 17(11):1541-1554. PubMed ID: 32791861 [TBL] [Abstract][Full Text] [Related]
37. Molecular Targets and Nanoparticulate Systems Designed for the Improved Therapeutic Intervention in Glioblastoma Multiforme. Akhter MH; Rizwanullah M; Ahmad J; Amin S; Ahmad MZ; Minhaj MA; Mujtaba MA; Ali J Drug Res (Stuttg); 2021 Mar; 71(3):122-137. PubMed ID: 33167048 [TBL] [Abstract][Full Text] [Related]
38. Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy. Zou Y; Wang Y; Xu S; Liu Y; Yin J; Lovejoy DB; Zheng M; Liang XJ; Park JB; Efremov YM; Ulasov I; Shi B Adv Mater; 2022 Aug; 34(33):e2203958. PubMed ID: 35738390 [TBL] [Abstract][Full Text] [Related]
39. A gain of function paradox: Targeted therapy for glioblastoma associated with abnormal NHE9 expression. Pall AE; Juratli L; Guntur D; Bandyopadhyay K; Kondapalli KC J Cell Mol Med; 2019 Nov; 23(11):7859-7872. PubMed ID: 31532058 [TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of targeted alpha therapy with Królicki L; Bruchertseifer F; Kunikowska J; Koziara H; Królicki B; Jakuciński M; Pawlak D; Apostolidis C; Mirzadeh S; Rola R; Merlo A; Morgenstern A Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):614-622. PubMed ID: 30498897 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]